FDA OKs First Device for Dialysis-Related AmyloidosisFDA OKs First Device for Dialysis-Related Amyloidosis
The authorization had a special humanitarian device exemption, used for a disease or condition that affects fewer than 4000 people in the United States each year. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 11, 2015 Category: Consumer Health News Tags: Nephrology News Alert Source Type: news

UCLA study shows feasibility of blood-based test for diagnosing Alzheimer’s Disease
UCLA researchers have provided the first evidence that a simple blood test could be developed to confirm the presence of beta amyloid proteins in the brain, which is a hallmark of Alzheimer’s disease. Although approximately 5 million Americans are living with Alzheimer’s, no reliable blood-based test currently exists for the neurodegenerative disorder that is the sixth-leading cause of death in the United States. Using blood-based biomarkers — a signature of proteins in the blood that indicate the presence of a disease — to diagnose Alzheimer’s could be a key advance. “Blood-based biomar...
Source: UCLA Newsroom: Health Sciences - March 11, 2015 Category: Universities & Medical Training Source Type: news

FDA Authorizes Use Of First Device To Treat Patients With Dialysis-Related Amyloidosis
The U.S. Food and Drug Administration recently authorized use of Lixelle Beta 2-microglobulin Apheresis Column, the first device to treat dialysis-related amyloidosis (DRA). (Source: Medical Design Online News)
Source: Medical Design Online News - March 10, 2015 Category: Medical Equipment Source Type: news

First Device Approved for Dialysis-Related Amyloidosis
Title: First Device Approved for Dialysis-Related AmyloidosisCategory: Health NewsCreated: 3/6/2015 12:00:00 AMLast Editorial Review: 3/9/2015 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - March 9, 2015 Category: Rheumatology Source Type: news

FDA authorizes use of first device to treat patients with dialysis-related amyloidosis
The U.S. Food and Drug Administration today authorized use of Lixelle Beta 2-microglobulin Apheresis Column, the first device to treat dialysis-related amyloidosis (DRA). (Source: Food and Drug Administration)
Source: Food and Drug Administration - March 6, 2015 Category: American Health Source Type: news

Amyloid formation may link Alzheimer disease and type 2 diabetes
The pathological process amyloidosis, in which misfolded proteins (amyloids) form insoluble fibril deposits, occurs in many diseases, including Alzheimer disease (AD) and type 2 diabetes mellitus (T2D). However, little is known about whether different forms of amyloid proteins interact or how amyloid formation begins in vivo. A new study has found evidence that amyloid from the brain can stimulate the growth of fibrils in the murine pancreas and pancreatic-related amyloid can be found along with brain-related amyloid in human brain senile plaques. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 17, 2015 Category: Science Source Type: news

Amyloid formation may link Alzheimer disease and type 2 diabetes
(Elsevier Health Sciences) The pathological process amyloidosis, in which misfolded proteins (amyloids) form insoluble fibril deposits, occurs in many diseases, including Alzheimer disease and type 2 diabetes. A study published in The American Journal of Pathology has found evidence that amyloid from the brain can stimulate the growth of fibrils in the murine pancreas and pancreatic-related amyloid can be found along with brain-related amyloid in human brain senile plaques. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 17, 2015 Category: Global & Universal Source Type: news

ASH: New Myeloma Regimens, AL Amyloidosis (CME/CE)
(MedPage Today) -- Add-on therapy with HDAC inhibitor improved outcomes in myeloma. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - December 15, 2014 Category: Consumer Health News Source Type: news

Prothena targets rare protein-misfolding disease in late-stage study
Elan Corp. spinout Prothena Corp. will take an experimental drug aimed at a rare protein-misfolding disease into a late-stage clinical trial, the company said Tuesday. Prothena (NASDAQ: PRTA), whose operations are largely based in South San Francisco, said it will focus its drug on amyloid light-chain amyloidosis, or AL amyloidosis, in what's expected to be a 230-patient, Phase III study. In the disease, misfolded amyloid proteins are deposited in tissue, causing progressive organ damage, including… (Source: bizjournals.com Health Care:Hospitals headlines)
Source: bizjournals.com Health Care:Hospitals headlines - December 2, 2014 Category: Hospital Management Authors: Ron Leuty Source Type: news

MRI and LV Remodelling in Cardiac AmyloidosisMRI and LV Remodelling in Cardiac Amyloidosis
Learn more about the morphological features and remodelling patterns of cardiac amyloidosis as seen with cardiac magnetic resonance imaging. Heart (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 20, 2014 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Alnylam begins DISCOVERY trial to track TTR mutation prevalence
Alnylam Pharmaceuticals has started the DISCOVERY trial of its investigational candidate ALN-TTRsc, to evaluate the prevalence of transthyretin (TTR) mutations in patients suspected of cardiac amyloidosis. (Source: Drug Development Technology)
Source: Drug Development Technology - September 25, 2014 Category: Pharmaceuticals Source Type: news

Hysterectomy Association Newsletter September 2014
Sourced from The Hysterectomy Association: Hysterectomy Association - Hysterectomy Association - hysterectomy, menopause and hormone replacement therapy (hrt) information and support for women. Welcome to the September newsletter. Well, my dire predictions of the summer ending thankfully didn’t come to anything and we seem to be enjoying a late summer bonus here in the UK. Hopefully that’s the case elsewhere in the world too. The Hysteria Writing Competition has finally closed to entries for this year and our judges are busy finishing off reading all the entries that arrived in the last week of August. When our...
Source: The Hysterectomy Association - September 11, 2014 Category: OBGYN Authors: Linda Parkinson-Hardman Tags: Newsletters Amyloidosis sleeping Source Type: news

Cardiac Amyloidosis: The Great ImitatorCardiac Amyloidosis: The Great Imitator
Three Mayo experts explain the three main types of cardiac amyloidosis and dispel some myths about the diagnosis and treatment of this rare condition. Mayo Clinic (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 8, 2014 Category: Cardiology Tags: Cardiology Roundtable Source Type: news

Amyloidosis – Can you help relieve the pressure?
Sourced from The Hysterectomy Association: Hysterectomy Association - Hysterectomy Association - hysterectomy, menopause and hormone replacement therapy (hrt) information and support for women. Have you ever heard of amyloidosis? Don’t worry, I hadn’t either! The good news is you don’t have to be an expert on this rare and dangerous disease to help lighten the load of its victims. Amyloidosis is a condition which causes an excessive build-up of proteins in the blood. These proteins form clusters called ‘amyloids’, which are deposited around the sufferer’s body, putting undue pressure on ...
Source: The Hysterectomy Association - September 2, 2014 Category: OBGYN Authors: Linda Parkinson-Hardman Tags: Health Conditions Amyloidosis invisible illness Source Type: news

Cajal-Retzius cell loss and amyloidosis in Alzheimer's disease
(Neural Regeneration Research) Cajal-Retzius cells are reelin-secreting neurons in the marginal zone of the neocortex and hippocampus. However, the relationship between Cajal-Retzius cells and Alzheimer's disease is unknown. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 5, 2014 Category: Biology Source Type: news

Widely-used anti-inflammatory drug shows success in treatment of amyloidosis
This study, published in the Dec. 25 issue of JAMA, is one of the first examples of successful repurposing of a generic drug to treat a rare disease. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 30, 2013 Category: Consumer Health News Tags: Neurology / Neuroscience Source Type: news

Widely-used anti-inflammatory drug shows success in treatment of amyloidosis
(Boston University Medical Center) A recent study led by researchers from the Amyloidosis Center at Boston University School of Medicine and Boston Medical Center demonstrates that diflunisal, a generic anti-inflammatory drug, successfully reduced neurological decline and preserved the quality of life in patients with familial transthyretin amyloidosis. Diflunisal is an inexpensive and safe medication marketed over the past 40 years for arthritis and pain. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - December 24, 2013 Category: Global & Universal Source Type: news

Alnylam starts Phase II study of ALN-TTRsc for treatment of TTR-mediated amyloidosis
US-based Alnylam Pharmaceuticals has started a pilot Phase II trial with ALN-TTRsc, a subcutaneously delivered RNAi therapeutic targeting the transthyretin (TTR) gene in development for the treatment of TTR-mediated amyloidosis (ATTR). (Source: Drug Development Technology)
Source: Drug Development Technology - December 18, 2013 Category: Pharmaceuticals Source Type: news

Familial amyloidosis modeled in vitro using iPSC technology
Researchers from Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) have generated the first known disease-specific induced pluripotent stem cell (iPSC) lines from a patient with familial transthyretin amyloidosis (ATTR). The findings, which are reported in Stem Cell Reports, may lead to new treatments for genetic diseases such as familial amyloidosis. iPSCs are a form of stem cells that come from skin or blood cells reprogrammed into cells that have the ability to become any type of tissue in the body... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 5, 2013 Category: Consumer Health News Tags: Stem Cell Research Source Type: news

Diagnosis: The Tell-Tale Green Heart
A very odd finding during routine surgery helps explain everything.     (Source: NYT Health)
Source: NYT Health - November 1, 2013 Category: Consumer Health News Authors: By LISA SANDERS, M.D. Tags: Heart Amyloidosis Surgery and Surgeons Source Type: news

Alnylam completes enrolment in Phase II Transthyretin-Mediated Amyloidosis clinical trial
Alnylam Pharmaceuticals has completed enrolment in its Phase II trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis (ATTR). (Source: Drug Development Technology)
Source: Drug Development Technology - October 2, 2013 Category: Pharmaceuticals Source Type: news

Biomarker IDs Fibrotic Heart Failure (CME/CE)
ORLANDO (MedPage Today) -- Galectin-3 (Gal-3), a biomarker for fibrosis, may have a role in identifying heart failure caused by cardiac amyloidosis, researchers suggested. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 24, 2013 Category: Cardiology Source Type: news

Experimental Drug Shows Promise for Rare Genetic Disorder
New therapy may combat amyloidosis, the potentially deadly disease caused by protein build-up in organs (Source: WebMD Health)
Source: WebMD Health - August 29, 2013 Category: Consumer Health News Source Type: news

Novel Approach to Amyloidosis Looks Promising (CME/CE)
(MedPage Today) -- An amyloidosis therapeutic strategy based on controlling gene expression passed a proof-of-concept test, suppressing transthyretin production in patients with transthyretin amyloidosis, investigators reported. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 29, 2013 Category: Cardiology Source Type: news

Experimental Drug Shows Promise for Rare Genetic Disorder
New therapy may combat amyloidosis, the potentially deadly disease caused by protein build-up in organs Source: HealthDay Related MedlinePlus Page: Amyloidosis (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - August 29, 2013 Category: Consumer Health News Source Type: news

Dreaming of animals and other warning signs of neurodegeneration | Mo Costandi
Sleep disturbances may be an early warning sign of Alzheimer's and other neurodegenerative diseasesThe latest issue of Nature contains an Outlook supplement about the health impacts of poor sleep, including a feature I wrote about the link between sleep disturbances and neurodegenerative diseases, called "Amyloid awakenings". The title refers to a process called amyloidosis, by which mutated, abnormally folded proteins aggregate to form insoluble clumps in the brain. Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - May 22, 2013 Category: Science Authors: Mo Costandi Tags: Neuroscience Sleep Health & wellbeing Alzheimer's Society Source Type: news

Prothena doses first patient in Phase I study of NEOD001
Clinical stage biotechnology company Prothena has dosed the first AL amyloidosis patient in its Phase I study of NEOD001, an antibody therapeutic candidate. (Source: Drug Development Technology)
Source: Drug Development Technology - April 24, 2013 Category: Pharmaceuticals Source Type: news

Detecting Cardiac Amyloidosis Using Amyloid Imaging
While amyloid imaging may now be most associated with detecting plaques in the brain, it has the potential to change the way cardiac amyloidosis is diagnosed. According to first-of-its-kind research published in the February issue of The Journal of Nuclear Medicine, positron emission tomography (PET) with 11C-PIB can positively visualize amyloid deposits in the heart. Currently there is no noninvasive test available for specific diagnosis. Cardiac amyloidosis is a deadly disorder caused by abnormal amyloid deposits in the heart tissue... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 7, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news

Amyloid Imaging May Help Detect Cardiac Amyloidosis
Amyloid imaging, used to detect plaques in the brain, may help diagnose cardiac amyloidosis, researchers said. (Source: Diagnostic Imaging)
Source: Diagnostic Imaging - February 5, 2013 Category: Radiology Source Type: news

Amyloid imaging shows promise for detecting cardiac amyloidosis
While amyloid imaging may now be most associated with detecting plaques in the brain, it has the potential to change the way cardiac amyloidosis is diagnosed. According to first-of-its-kind research, positron emission tomography with 11C-PIB can positively visualize amyloid deposits in the heart. Currently there is no noninvasive test available for specific diagnosis. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 4, 2013 Category: Science Source Type: news

Amyloid imaging shows promise for detecting cardiac amyloidosis
(Society of Nuclear Medicine) While amyloid imaging may now be most associated with detecting plaques in the brain, it has the potential to change the way cardiac amyloidosis is diagnosed. According to first-of-its-kind research published in the February issue of The Journal of Nuclear Medicine, positron emission tomography with 11C-PIB can positively visualize amyloid deposits in the heart. Currently there is no noninvasive test available for specific diagnosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 4, 2013 Category: Global & Universal Source Type: news